Maiden Pharma seeks to reopen Sonipat plant after DCGI clearance

However, the DCGI has now said the cough syrups in question were found not to be contaminated, and met with government standards

Haryana-based Maiden Pharmaceuticals, which was in the eye of the storm after cough syrups manufactured at its Sonipat plant were linked to child deaths in Gambia, is looking to reopen the facility once it gets final clearance from the national drug regulator.

The state’s Food and Drugs Administration (FDA) has written to the Drugs Controller General of India (DCGI), requesting him to form a joint committee with central and state officers to inspect the plant. “We had raised questions on GMP (good manufacturing practices) compliance and sent a notice to Maiden Pharma. The company has replied, claiming it has taken action,”